Values First Advisors Inc. bought a new position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 2,072 shares of the company's stock, valued at approximately $329,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in INSP. Dragoneer Investment Group LLC acquired a new stake in Inspire Medical Systems during the 4th quarter worth approximately $161,486,000. Congress Asset Management Co. raised its holdings in Inspire Medical Systems by 3,943.6% in the 1st quarter. Congress Asset Management Co. now owns 307,555 shares of the company's stock valued at $48,987,000 after acquiring an additional 299,949 shares in the last quarter. Marshall Wace LLP raised its holdings in Inspire Medical Systems by 1,775.3% in the 4th quarter. Marshall Wace LLP now owns 277,131 shares of the company's stock valued at $51,375,000 after acquiring an additional 262,353 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Inspire Medical Systems in the 4th quarter valued at $47,604,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Inspire Medical Systems by 869.9% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 210,160 shares of the company's stock valued at $38,959,000 after acquiring an additional 188,492 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on INSP. Robert W. Baird lifted their price objective on Inspire Medical Systems from $230.00 to $236.00 and gave the company an "outperform" rating in a report on Tuesday, May 6th. KeyCorp lowered their price target on Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Wells Fargo & Company lowered their price target on Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Stifel Nicolaus reduced their price objective on Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. Finally, Morgan Stanley reduced their price objective on Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $211.91.
View Our Latest Stock Report on INSP
Inspire Medical Systems Stock Up 3.6%
Shares of NYSE INSP traded up $4.82 during trading on Thursday, reaching $139.27. The company had a trading volume of 835,854 shares, compared to its average volume of 555,184. The company's fifty day moving average price is $140.04 and its 200-day moving average price is $162.37. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $225.00. The stock has a market cap of $4.11 billion, a P/E ratio of 64.18, a PEG ratio of 2.04 and a beta of 1.25.
Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.33. Inspire Medical Systems had a return on equity of 10.00% and a net margin of 7.92%. The firm had revenue of $201.32 million for the quarter, compared to analyst estimates of $194.89 million. During the same quarter in the previous year, the company posted ($0.34) EPS. The business's revenue was up 22.7% on a year-over-year basis. As a group, equities analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.
Insider Activity at Inspire Medical Systems
In other Inspire Medical Systems news, Director Shawn Mccormick sold 360 shares of the company's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $160.00, for a total value of $57,600.00. Following the sale, the director owned 24,046 shares in the company, valued at approximately $3,847,360. The trade was a 1.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.10% of the company's stock.
Inspire Medical Systems Profile
(
Free Report)
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
Recommended Stories

Before you consider Inspire Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.
While Inspire Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.